In vivo growth rates are poorly correlated with phage therapy success in a mouse infection model

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 2, 2012, Pages 949-954

  Bull, J J ^a   Otto, G ^a   Molineux, I J ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL INFECTION; BACTERIAL MEMBRANE; BACTERIAL STRAIN; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; GROWTH RATE; IN VIVO STUDY; INOCULATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEOMICS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL CAPSULES; COLIPHAGES; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; MICE; TREATMENT OUTCOME;

EID: 84856077735     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05842-11     Document Type: Article

References (37)

1. Adams MH. 1959. Bacteriophages. Interscience Publishers, New York, NY.
2. Biswas B, et al. 2002. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect. Immun. 70:204-210. (Pubitemid 34028619)
3. Brussow H. 2005. Phage therapy: the Escherichia coli experience. Microbiology 151:2133-2140. (Pubitemid 40984287)
4. Bruttin A, Brussow H. 2005. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob. Agents Chemother. 49:2874-2878. (Pubitemid 40917605)
5. Bull JJ. 2006. Optimality models of phage life history and parallels in disease evolution. J. Theor. Biol. 241:928-938. (Pubitemid 44080797)
6. Bull JJ, Levin BR, DeRouin T, Walker N, Bloch CA. 2002. Dynamics of success and failure in phage and antibiotic therapy in experimental infections. BMC Microbiol. 2:35.
7. Bull JJ, Regoes RR. 2006. Pharmacodynamics of non-replicating viruses, bacteriocins and lysins. Proc. Biol. Sci. 273:2703-2712. (Pubitemid 44671913)
8. Bull JJ, Vimr ER, Molineux IJ. 2010. A tale of tails: sialidase is key to success in a model of phage therapy against K1-capsulated Escherichia coli. Virology 398:79-86.
9. Carlton RM, Noordman WH, Biswas B, de Meester ED, Loessner MJ. 2005. Bacteriophage P100 for control of Listeria monocytogenes in foods: genome sequence, bioinformatic analyses, oral toxicity study, and application. Regul. Toxicol. Pharmacol. 43:301-312. (Pubitemid 41616396)
10. Coates AR, Hu Y. 2007. Novel approaches to developing new antibiotics for bacterial infections. Br. J. Pharmacol. 152:1147-1154. (Pubitemid 350242433)
11. Gross RJ, Cheasty T, Rowe B. 1977. Isolation of bacteriophages specific for the K1 polysaccharide antigen of Escherichia coli. J. Clin. Microbiol. 6:548-550. (Pubitemid 8252853)
12. Hanlon GW. 2007. Bacteriophages: an appraisal of their role in the treatment of bacterial infections. Int. J. Antimicrob. Agents 30:118-128. (Pubitemid 46977193)
13. Leverentz B, et al. 2003. Biocontrol of Listeria monocytogenes on freshcut produce by treatment with lytic bacteriophages and a bacteriocin. Appl. Environ. Microbiol. 69:4519-4526. (Pubitemid 36992907)
14. Levin BR, Bull JJ. 1996. Phage therapy revisited: the population biology of a bacterial infection and its treatment with bacteriophage and antibiotics. Am. Nat. 147:881-898.
15. Levin BR, Bull JJ. 2004. Population and evolutionary dynamics of phage therapy. Nat. Rev. Microbiol. 2:166-173. (Pubitemid 39490070)
16. Levin BR, Stewart FM, Chao L. 1977. Resource-limited growth, competition, and predation - a model and experimental studies with bacteria and bacteriophage. Am. Nat. 111:3-24.
17. Matsuda T, et al. 2005. Lysis-deficient bacteriophage therapy decreases endotoxin and inflammatory mediator release and improves survival in a murine peritonitis model. Surgery 137:639-646. (Pubitemid 40755421)
18. Mattey M, Spencer J. 2008. Bacteriophage therapy-cooked goose or phoenix rising? Curr. Opin. Biotechnol. 19:608-612.
19. Merabishvili M, et al. 2009. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One 4:e4944.
20. Merril CR, et al. 1996. Long-circulating bacteriophage as antibacterial agents. Proc. Natl. Acad. Sci. U. S. A. 93:3188-3192. (Pubitemid 26125592)
21. Mushtaq N, Redpath MB, Luzio JP, Taylor PW. 2004. Prevention and cure of systemic Escherichia coli K1 infection by modification of the bacterial phenotype. Antimicrob. Agents Chemother. 48:1503-1508. (Pubitemid 38544351)
22. Payne RJ, Jansen VA. 2003. Pharmacokinetic principles of bacteriophage therapy. Clin. Pharmacokinet. 42:315-325. (Pubitemid 36433874)
23. Payne RJ, Jansen VA. 2001. Understanding bacteriophage therapy as a density-dependent kinetic process. J. Theor. Biol. 208:37-48. (Pubitemid 32055739)
24. Pirnay JP, et al. 2011. The phage therapy paradigm: pret-a-porter or sur-mesure? Pharm. Res. 28:934-937.
25. Projan S. 2004. Phage-inspired antibiotics? Nat. Biotechnol. 22:167-168. (Pubitemid 38160528)
26. Radetsky P. 1996. The good virus. Discover 17:52.
27. Rhoads DD, et al. 2009. Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J. Wound Care 18:237-238, 240-243.
28. Scholl D, Rogers S, Adhya S, Merril CR. 2001. Bacteriophage K1-5 encodes two different tail fiber proteins, allowing it to infect and replicate on both K1 and K5 strains of Escherichia coli. J. Virol. 75:2509-2515. (Pubitemid 32185014)
29. Schoolnik GK, Summers WC, Watson JD. 2004. Phage offer a real alternative. Nat. Biotechnol. 22:505-507.
30. Smith HW, Huggins MB. 1983. Effectiveness of phages in treating experimental Escherichia coli diarrhoea in calves, piglets and lambs. J. Gen. Microbiol. 129:2659-2675. (Pubitemid 13039611)
31. Smith HW, Huggins MB. 1982. Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J. Gen. Microbiol. 128:307-318. (Pubitemid 12159900)
32. Soothill J, Hawkins C, Anggard E, Harper D. 2004. Therapeutic use of bacteriophages. Lancet Infect. Dis. 4:544-545. (Pubitemid 39141794)
33. Sulakvelidze A. 2005. Phage therapy: an attractive option for dealing with antibiotic-resistant bacterial infections. Drug Discov. Today 10:807-809. (Pubitemid 40824730)
34. Sulakvelidze A, Alavidze Z, Morris JG, Jr. 2001. Bacteriophage therapy. Antimicrob. Agents Chemother. 45:649-659. (Pubitemid 32182003)
35. Sulakvelidze A, Morris JG, Jr. 2001. Bacteriophages as therapeutic agents. Ann. Med. 33:507-509. (Pubitemid 33052270)
36. Summers WC. 2001. Bacteriophage therapy. Annu. Rev. Microbiol. 55:437-451. (Pubitemid 32978113)
37. Wright A, Hawkins CH, Anggard EE, Harper DR. 2009. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa: a preliminary report of efficacy. Clin. Otolaryngol. 34:349-357.